Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or
Patents for C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
11/2005
11/24/2005WO2005111039A2 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
11/24/2005WO2005111003A1 Amino-tetrazoles analogues and methods of use
11/24/2005WO2005110992A1 Amido compounds and their use as pharmaceuticals
11/24/2005WO2005110410A2 Kinase inhibitors as therapeutic agents
11/24/2005WO2005079192A3 Novel treatment
11/24/2005WO2005073213A3 Method for the production of 3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol derivatives
11/24/2005US20050261497 Catalytic asymmetric hetero diels-alder reaction of a heteroaromatic C-nitroso dienophile: a novel method for synthesis of chiral non-racemic amino alcohols
11/24/2005US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis
11/24/2005US20050261493 Methods for the isolation and purification of ansamitocins
11/24/2005US20050261356 Methods and compositions for the treatment of chronic lymphocytic leukemia
11/24/2005US20050261326 Metabolites of ecteinascidin 743
11/24/2005US20050261322 HIV integrase inhibitors
11/24/2005US20050261313 For angiogenesis mediated diseases; cancer; acylation, cyclization and Heck-type reduction
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261296 Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
11/24/2005US20050261263 Benzoquinone ansamycins
11/24/2005US20050261262 Rifamycin derivatives effective against drug-resistant microbes
11/24/2005CA2566158A1 Kinase inhibitors as therapeutic agents
11/24/2005CA2565238A1 Amido compounds and their use as pharmaceuticals
11/24/2005CA2565211A1 Amino-tetrazoles analogues and methods of use
11/23/2005EP1598356A1 Method for preparing polymorphism of irinotecan hydrochloride
11/23/2005EP1598355A1 Therapeutic agent for schizophrenia
11/23/2005EP1597262A2 Substituted heterocycles
11/23/2005EP1597256A1 N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
11/23/2005EP1597254A1 Indole-derivative modulators of steroid hormone nuclear receptors
11/23/2005EP1597084A2 Imaging system
11/23/2005EP1272480B1 Method for the production of spirocyclic tetronic acid derivatives
11/23/2005EP1204638B1 Biphenyl-substituted cyclic keto enols as pesticides
11/23/2005CN1701076A Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
11/23/2005CN1701075A Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
11/23/2005CN1700859A Nodulisporic acid derivative spot-on formulations for combating parasites
11/23/2005CN1699350A Processes and intermediates for preparing anti-cancer compounds
11/23/2005CN1228341C Process for producing camptothecin
11/23/2005CN1228340C Method for purifying 20(S)-camptothecin
11/22/2005US6967216 Neuropeptide Y receptor modulators; treating eating disorders
11/22/2005US6967079 Pyrimidine derivatives for labeled binding partners
11/17/2005WO2005108389A1 Indole derivatives having piperidine rings
11/17/2005WO2005108368A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005WO2005107762A2 Certain chemical entities, compositions, and methods
11/17/2005WO2005107760A1 Compounds and compositions as inducers of keratinocyte differentiation
11/17/2005WO2005107742A1 Novel antiviral helioxanthin analogs
11/17/2005WO2005095401A8 Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005WO2005016264A3 Diamine derivatives of quinone and uses thereof
11/17/2005US20050256309 Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
11/17/2005US20050256185 Spiro and dispiro 1,2,4-trioxolane antimalarials
11/17/2005US20050256176 Sulphonamide derivatives and their use as tace inhibitors
11/17/2005US20050256148 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; parasitic or viral infections
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256136 1-[2-(3-Ethyl-ureido)-3H-benzoimidazol-5-yl]-1H-imiazole-4-carboxylic acid methyl ester; bacteriostatic antibiotic; decrease antibiotic resistance of bacterial organisms; new class of compounds for bacterial infections
11/17/2005US20050256124 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
11/17/2005US20050256114 substituted 4H-benzo[1,4]oxazin-3-one derivatives, having antagonistic activity at muscarinic receptors and agonistic activity at adrenergic receptors; chronic obstructive pulmonary disease; asthma; bronchitis; adult respiratory distress syndrome
11/17/2005US20050256109 HIV integrase inhibitors: cyclic pyrimidinone compounds
11/17/2005US20050256104 Protease inhibitors
11/17/2005US20050256103 Indole derivative having piperidine ring
11/17/2005US20050256102 Inhibit Aurora kinase; cancer; 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-methylamino-ethyl)-benzamide; 9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine
11/17/2005US20050256101 Plant extracts and alkaloids having antitussive activity
11/17/2005US20050256096 Having another functional group or pharmacophore covalently attached through a carbamate linkage, e.g., 25-O-Desacetyl-N-(1-carbonyl-4-methyl-piperazine) 3-morpholino rifamycin S; dual-function antibiotic mechanism provides for reduced frequency of resistance.
11/17/2005US20050256089 for use as pesticides, herbicides; condensation
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050255475 Energy transfer dyes, terminators and use thereof
11/17/2005US20050255465 Novel fluorescent label compounds
11/17/2005CA2568241A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005CA2565695A1 Certain chemical entities and compositions for use in the treatment of a cellular proliferative disease or disorder
11/16/2005EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1594873A1 Pyrrolidinohydrochinazolines
11/16/2005EP1594867A2 Phenylacetamides and their use as glucokinase modulators
11/16/2005EP1594495A1 Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
11/16/2005EP1476429B1 Novel pyridine- and quinoline-derivatives
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1347982B1 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
11/16/2005EP0981517B1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides
11/16/2005CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists
11/16/2005CN1696131A Method for extracting galanthamine from raw materials of genera of lycoris radiata or snowdrop
11/16/2005CN1227254C Pyridone compound and its prepn process
11/16/2005CN1227012C Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
11/15/2005US6964979 Liver disorders
11/15/2005US6964964 Anticancer agents
11/15/2005CA2330351C New linear or cyclical ureas, their preparation process and the pharmaceutical compositions which contain them
11/15/2005CA2248802C Meso-substituted tripyrrane compounds, compositions, and methods for making and using the same
11/15/2005CA2207627C 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
11/10/2005WO2005106007A1 Labeling of rapamycin using rapamycin-specific methylases
11/10/2005WO2005105811A1 Regiospecific synthesis of rapamycin 42-ester derivatives
11/10/2005WO2005105809A1 Thienopyridines as ikk inhibitors
11/10/2005WO2005105808A1 Thienopyridazines as ikk inhibitors
11/10/2005WO2005105760A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005US20050250808 Each compound having an azabicyclic ring attached via a ring N or amino group; neuroprotectants; neurodegenerative diseases, analgesics, psychological disorders; e.g. 5-Methoxy-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxamide; ligands for nicotinic acetylcholine receptors
11/10/2005US20050250802 Novel substituted amines of spirofuropyridines useful in therapy
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250782 Heterocyclic inhibitors of MEK and methods of use thereof
11/10/2005US20050250770 Fused heterocyclic compounds
11/10/2005US20050250765 Diazepinones as antiviral agents
11/10/2005US20050250751 neo-tanshinlactone is excluded; treating cancer
11/10/2005US20050250047 Light-fast, high-capacity optical storage media
11/10/2005CA2564085A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005CA2563990A1 Thienopyridazines as ikk inhibitors
11/10/2005CA2563982A1 Thienopyridines as ikk inhibitors
11/10/2005CA2562952A1 Regiospecific synthesis of rapamycin 42-ester derivatives
11/10/2005CA2562164A1 Labeling of rapamycin using rapamycin-specific methylases
1 ... 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 ... 298